Chimerix’s Brincidofovir Selected for Use in Ebola Clinical Trial in West Africa by International Consortium
DURHAM, N.C., Nov. 13, 2014 (GLOBE NEWSWIRE) — Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced that its investigational broad-spectrum antiviral brincidofovir has been selected as one of two investigational agents to be evaluated in a clinical study in patients with confirmed Ebola Virus Disease in west Africa. Chimerix and the University of Oxford are in the process of finalizing a definitive agreement for supplying brincidofovir for the planned clinical trial.
© 2021 Pappas Capital, LLC. ALL RIGHTS RESERVED.